X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6) 6
melanoma (6) 6
nivolumab (6) 6
apoptosis (5) 5
female (5) 5
male (5) 5
cancer (4) 4
index medicus (4) 4
middle aged (4) 4
programmed cell death 1 receptor - antagonists & inhibitors (4) 4
treatment outcome (4) 4
aged (3) 3
care and treatment (3) 3
cell death (3) 3
immunotherapy (3) 3
ipilimumab (3) 3
melanoma - drug therapy (3) 3
melanoma - pathology (3) 3
metastasis (3) 3
patients (3) 3
programmed cell death 1 receptor - immunology (3) 3
retrospective studies (3) 3
abridged index medicus (2) 2
acral melanoma (2) 2
adult (2) 2
aged, 80 and over (2) 2
antibodies, monoclonal - adverse effects (2) 2
antibodies, monoclonal, humanized - administration & dosage (2) 2
antigens (2) 2
antineoplastic agents - adverse effects (2) 2
brain metastases (2) 2
brain neoplasms - immunology (2) 2
brain neoplasms - secondary (2) 2
case report (2) 2
dermatology (2) 2
drug therapy (2) 2
follow-up studies (2) 2
immune checkpoint (2) 2
lung cancer (2) 2
lymphocytes (2) 2
melanoma - immunology (2) 2
melanoma - therapy (2) 2
metastases (2) 2
movement disorders (2) 2
mucosa (2) 2
mucosal melanoma (2) 2
neoplasm staging (2) 2
oncology (2) 2
pembrolizumab (2) 2
prognosis (2) 2
safety (2) 2
skin neoplasms - drug therapy (2) 2
skin neoplasms - pathology (2) 2
survival (2) 2
survival rate (2) 2
adenocarcinoma (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - pathology (1) 1
adenocarcinoma of lung (1) 1
administration, oral (1) 1
administration, topical (1) 1
angina pectoris (1) 1
anti-cytotoxic t-iymphocyte-associated protein 4 (1) 1
anti-cytotoxic t-lymphocyte-associated protein 4 (1) 1
anti-pd-1 (1) 1
anti-pd-1 therapy (1) 1
anti-programmed cell death protein 1 (1) 1
anti-programmed cell death receptor 1 (1) 1
anti-programmed cell death-1 antibodies (1) 1
anti-programmed cell death-1 monoclonal antibodies (1) 1
anti-programmed death 1 therapy (1) 1
anti-programmed death cell receptor-1 (1) 1
anti-programmed death-1 receptor (1) 1
antibodies, monoclonal - administration & dosage (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antineoplastic agents, immunological - administration & dosage (1) 1
antineoplastic agents, immunological - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
anti‐programmed cell death receptor 1 (1) 1
anti‐programmed cell death‐1 antibodies (1) 1
anti‐programmed death 1 therapy (1) 1
anti‐programmed death cell receptor‐1 (1) 1
anti‐programmed death‐1 receptor (1) 1
anti–cytotoxic t‐lymphocyte‐associated protein 4 (1) 1
anti–programmed cell death protein 1 (1) 1
article (1) 1
articles (1) 1
atrophy (1) 1
autoantibodies (1) 1
autoimmunity (1) 1
biochemistry (1) 1
biochemotherapy (1) 1
biomarkers (1) 1
biopsy (1) 1
blockade (1) 1
blood sugar (1) 1
blood sugar monitoring (1) 1
brain neoplasms - drug therapy (1) 1
brain neoplasms - therapy (1) 1
cancer therapies (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 11/2016, Volume 122, Issue 21, pp. 3354 - 3362
Journal Article
Cancer, ISSN 0008-543X, 10/2016, Volume 122, Issue 19, pp. 3051 - 3058
Journal Article
The Journal of Dermatology, ISSN 0385-2407, 05/2018, Volume 45, Issue 5, pp. 587 - 591
Anti‐programmed cell death receptor‐1 (PD‐1) antibodies represent an effective treatment opinion for advanced melanoma and non‐small‐cell lung cancer, as well... 
immune checkpoint inhibitor | immune‐related adverse events | nivolumab | anti‐programmed death cell receptor‐1 | oral lichenoid reaction | anti-programmed death cell receptor-1 | immune-related adverse events | ANTI-PD-1 THERAPY | SAFETY | PLANUS | CANCER | DERMATOLOGY | Lung Neoplasms - drug therapy | Glucocorticoids - therapeutic use | Adenocarcinoma - pathology | Lichenoid Eruptions - drug therapy | Adenocarcinoma of Lung | Mouth - drug effects | Humans | Lichenoid Eruptions - chemically induced | Antibodies, Monoclonal - adverse effects | Ulcer - epidemiology | Lung Neoplasms - pathology | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Incidence | Ulcer - pathology | Antineoplastic Agents - adverse effects | Ulcer - drug therapy | Female | Skin - pathology | Administration, Oral | Treatment Outcome | Adenocarcinoma - drug therapy | Lichenoid Eruptions - pathology | Ulcer - chemically induced | Biopsy | Lichenoid Eruptions - epidemiology | Nivolumab | Mouth - pathology | Quality of Life | Aged | Administration, Topical | Skin - drug effects | Lung cancer, Non-small cell | Cell death | Ulcers | Corticoids | Tongue | Endocrine system | Lung cancer | Liver | Mucosa | Melanoma | Dermis | Gastrointestinal tract | Patients | Quality of life | Immune checkpoint | Skin | Apoptosis
Journal Article
Journal of Diabetes Investigation, ISSN 2040-1116, 11/2016, Volume 7, Issue 6, pp. 915 - 918
Journal Article
The Journal of Dermatology, ISSN 0385-2407, 04/2019, Volume 46, Issue 4, pp. 328 - 333
Journal Article
Muscle & Nerve, ISSN 0148-639X, 12/2017, Volume 56, Issue 6, pp. E162 - E167
ABSTRACT Introduction Pembrolizumab, a monoclonal antibody directed against the immune checkpoint programmed cell death‐1 receptor (PD‐1), has improved... 
pembrolizumab | toxic neuropathy | immune neuropathy | polyradiculoneuropathy | anti‐programmed death‐1 receptor | GUILLAIN-BARRE-SYNDROME | CNS DEMYELINATION | anti-programmed death-1 receptor | CANCER | NEUROSCIENCES | CLINICAL NEUROLOGY | THERAPY | MULTIPLE-SCLEROSIS | PATIENT | CHECKPOINT | MYASTHENIA-GRAVIS | NIVOLUMAB | IPILIMUMAB TREATMENT | Polyradiculopathy - complications | Antibodies, Monoclonal, Humanized - adverse effects | Melanoma - complications | Skin Neoplasms - drug therapy | Humans | Muscle Weakness - complications | Male | Treatment Outcome | Skin Neoplasms - complications | Antineoplastic Agents, Immunological - adverse effects | Muscle Weakness - diagnostic imaging | Melanoma - drug therapy | Muscle Weakness - chemically induced | Adult | Polyradiculopathy - diagnostic imaging | Polyradiculopathy - chemically induced | Care and treatment | Cell death | Melanoma | Monoclonal antibodies | GABA | Metastasis | Drug therapy | Cancer | Drugs | Intravenous administration | Parkinson's disease | PD-1 protein | Cerebrospinal fluid | Foaming agents | Immunosuppressive agents | Metastases | Atrophy | Fibrillation | Movement disorders | Limbs | Cell survival | Neurodegenerative diseases | Complications | Side effects | Immune checkpoint | Magnetic resonance imaging | Steroid hormones | Steroids | Apoptosis | Index Medicus
Journal Article
Case Reports in Oncology, ISSN 1662-6575, 09/2017, Volume 10, Issue 3, pp. 809 - 812
We report a 69-year-old female patient with advanced lung cancer who developed myocarditis concomitant with myasthenia gravis (MG), also known as... 
Case Report | Adenocarcinoma | Myocarditis | Myasthenia gravis | Immunotherapy | Lung cancer | Nivolumab | Anti-programmed cell death-1 monoclonal antibodies | Herzmyasthenie | Heart | Edema | Pathology | Antigens | Immunoglobulins | Hospitals | Lymphocytes | Gangrene | Angina pectoris | Patients | Apoptosis
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.